Say hello to MassDevice +3, a bite-sized view of the top three medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
Boston Scientific’s S-ICD device is safe for use in patients with some forms of congenital heart defect, researchers said today at the annual Heart Rhythm Society meeting in Boston.
The S-ICD device is a “leadless” implantable cardioverter defibrillator that, unlike other ICDs, delivers its regulating shock via subcutaneous leads rather than leads threaded through blood vessels to the heart. Read more
Researchers reported on a study of Abbott’s MitraClip in patients with implanted cardiac rhythm devices showing a 50% overall reduction in ventricular tachyarrhythmias.
Presented at the annual Heart Rhythm Society meeting in Boston, the study followed 50 patients with existing cardiac devices before and after they received the MitraClip, which is designed to repair leaky mitral valves. Read more
Cryoablation is as effective as radio-frequency ablation in treating paroxysmal atrial fibrillations, researchers reported at the Heart Rhythm Society’s annual meeting in Boston.
The 5-year Freeze AF study involved 315 patients treated for paroxysmal atrial fibrillation, who were randomly assigned to either cryoablation or irrigated RF ablation treatments. Read more